ORCHESTRA BIOMED HOLDINGS IN (OBIO)
US68572M1062 - Common Stock
OBIO gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 191 industry peers in the Health Care Equipment & Supplies industry. The financial health of OBIO is average, but there are quite some concerns on its profitability. OBIO is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
OBIO had negative earnings in the past year.
In the past year OBIO has reported a negative cash flow from operations.
1.2 Ratios
With a Return On Assets value of -76.59%, OBIO is not doing good in the industry: 77.25% of the companies in the same industry are doing better.
OBIO has a Return On Equity of -124.81%. This is in the lower half of the industry: OBIO underperforms 68.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -76.59% | ||
| ROE | -124.81% | ||
| ROIC | N/A |
ROA(3y)-86.31%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of OBIO (92.71%) is better than 100.00% of its industry peers.
In the last couple of years the Gross Margin of OBIO has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for OBIO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 92.71% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.49%
GM growth 5YN/A
2. Health
2.1 Basic Checks
OBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for OBIO has been increased compared to 1 year ago.
OBIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -3.09, we must say that OBIO is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -3.09, OBIO is not doing good in the industry: 65.61% of the companies in the same industry are doing better.
OBIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.09 |
ROIC/WACCN/A
WACC9.3%
2.3 Liquidity
OBIO has a Current Ratio of 4.23. This indicates that OBIO is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of OBIO (4.23) is better than 71.43% of its industry peers.
OBIO has a Quick Ratio of 4.21. This indicates that OBIO is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of OBIO (4.21) is better than 76.72% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.23 | ||
| Quick Ratio | 4.21 |
3. Growth
3.1 Past
The earnings per share for OBIO have decreased strongly by -10.93% in the last year.
The Revenue for OBIO has decreased by -26.47% in the past year. This is quite bad
Measured over the past years, OBIO shows a very negative growth in Revenue. The Revenue has been decreasing by -21.47% on average per year.
EPS 1Y (TTM)-10.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7.89%
Revenue 1Y (TTM)-26.47%
Revenue growth 3Y-21.47%
Revenue growth 5YN/A
Sales Q2Q%135.56%
3.2 Future
The Earnings Per Share is expected to grow by 5.82% on average over the next years.
OBIO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 50.84% yearly.
EPS Next Y-12.8%
EPS Next 2Y-15.28%
EPS Next 3Y-5.26%
EPS Next 5Y5.82%
Revenue Next Year-5%
Revenue Next 2Y5.27%
Revenue Next 3Y3.53%
Revenue Next 5Y50.84%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for OBIO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OBIO. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as OBIO's earnings are expected to decrease with -5.26% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.28%
EPS Next 3Y-5.26%
5. Dividend
5.1 Amount
No dividends for OBIO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ORCHESTRA BIOMED HOLDINGS IN
NASDAQ:OBIO (1/14/2025, 8:00:02 PM)
After market: 5.27 0 (0%)5.27
+0.14 (+2.73%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners41.02%
Inst Owner Change0%
Ins Owners4.21%
Ins Owner Change-82.56%
Market Cap200.31M
Analysts83.64
Price Target14.79 (180.65%)
Short Float %2.81%
Short Ratio6.48
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.9%
Min EPS beat(2)-12.33%
Max EPS beat(2)6.52%
EPS beat(4)3
Avg EPS beat(4)1.06%
Min EPS beat(4)-12.33%
Max EPS beat(4)6.52%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)12.68%
Min Revenue beat(2)-10.63%
Max Revenue beat(2)36%
Revenue beat(4)1
Avg Revenue beat(4)-20.97%
Min Revenue beat(4)-74.16%
Max Revenue beat(4)36%
Revenue beat(8)3
Avg Revenue beat(8)-6.47%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-7.05%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-11.55%
EPS NY rev (1m)0.1%
EPS NY rev (3m)1.11%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-20.64%
Revenue NY rev (1m)9.09%
Revenue NY rev (3m)13.86%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 75.68 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 4.33 | ||
| P/tB | 4.33 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.61
EYN/A
EPS(NY)-1.99
Fwd EYN/A
FCF(TTM)-1.27
FCFYN/A
OCF(TTM)-1.26
OCFYN/A
SpS0.07
BVpS1.22
TBVpS1.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -76.59% | ||
| ROE | -124.81% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 92.71% | ||
| FCFM | N/A |
ROA(3y)-86.31%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.49%
GM growth 5YN/A
F-Score3
Asset Turnover0.04
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 62.2% | ||
| Cap/Sales | 6.84% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.23 | ||
| Quick Ratio | 4.21 | ||
| Altman-Z | -3.09 |
F-Score3
WACC9.3%
ROIC/WACCN/A
Cap/Depr(3y)148.45%
Cap/Depr(5y)N/A
Cap/Sales(3y)18.05%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-10.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7.89%
EPS Next Y-12.8%
EPS Next 2Y-15.28%
EPS Next 3Y-5.26%
EPS Next 5Y5.82%
Revenue 1Y (TTM)-26.47%
Revenue growth 3Y-21.47%
Revenue growth 5YN/A
Sales Q2Q%135.56%
Revenue Next Year-5%
Revenue Next 2Y5.27%
Revenue Next 3Y3.53%
Revenue Next 5Y50.84%
EBIT growth 1Y-23.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-20.54%
EBIT Next 3Y-6.98%
EBIT Next 5YN/A
FCF growth 1Y-86.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-90.77%
OCF growth 3YN/A
OCF growth 5YN/A